FDA Grants Fast Track Designation To CX-01 For The ... - AML Hub

All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

• Steering committee

• About us

• Newsletter

• Contact

• Our hubs

LOGIN MY aml HUBMY BOOKMARKED CONTENTACCOUNT SETTINGS

LOG OUT

You're logged in! Click here any time to manage your account or log out.

Brought to you by

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie,  and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

• Types

• Therapeutics

• Congresses

• Trials

• Expert Opinions

• Drug Updates

• Educational Resources

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Make a one-off contributionMake a repeat contributionFind out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View AML content recommended for you

First, please enter your email address to sign in or create your account.

Your email address

The personal information collected is utilized for the purposes defined within the privacy policy. We do not share your information with any third parties.

CONTINUEFDA grants Fast Track Designation to CX-01 for the treatment of patients with newly diagnosed acute myeloid leukemia

By Cynthia Umukoro

Share:

Aug 28, 2018

Bookmark this article

On 27th August 2018, the US Food and Drug Administration (FDA) granted Fast Track Designation to CX-01, a low anti-coagulant heparin, for the treatment of patients aged over 60 receiving induction therapy for newly diagnosed acute myeloid leukemia (AML).1 In January 2018, CX-01 was granted Orphan Drug Designation by the FDA for the treatment of AML.

Therapy for AML is associated with pancytopenia and a high failure rate due to resistant leukemia stem cells that use CXCL12/CXCR4 axis to home to marrow niches. Additionally, Platelet Factor 4 (PF4) negatively regulates bone marrow recovery after chemotherapy. CX-01 binds and inhibits PF4, thus neutralizing its activity and may also disrupt the CXCL12/CXCR4 axis, therefore improving the efficacy of AML therapy.

Preliminary data from a phase IIa non-randomized trial have demonstrated that CX-01 in combination with induction chemotherapy is well-tolerated and may enhance count recovery and treatment efficacy in patients with newly diagnosed primary AML.2 The drug manufacturers, Cantex Pharmaceuticals, noted that the Fast Track Designation granted by the FDA to CX-01 “represents recognition of CX-01's potential to address a significant unmet need in the treatment of AML by enhancing the efficacy of front-line AML chemotherapy”.

At present, CX-01 is being explored in a phase II randomized study (NCT02873338) in combination with standard chemotherapy for patients with newly diagnosed AML. CX-01 is also being evaluated in a phase I study (NCT02995655) in combination with azacitidine for patients with relapsed or refractory AML.

References

Newsletter

Subscribe to get the best content delivered to your inbox

First nameLast nameEmail addressOccupationSelect your occupation

Areas of interest

TypesTheraputicsCongressesTrialsExpert opinionsI agree to the AML Hub Terms & Conditions*Please tick this box if you consent to receiving information from the pharmaceutical industry and other hub stakeholders. This information may be promotional in nature and is not associated with the AML Hub.SIGN ME UP